GlaxoSmithKline agreed to pay $70 million to settle state Medicaid claims involving Zofran and Kytril, drugs used for the treatment of cancer.  In what a Glaxo spokesperson claimed was a common practice, the allegations included claims that the prices set for these drugs were based on fraudulent inflated figures provided by Glaxo, resulting in increased reimbursement from government programs.

For more information, click here.